Promising agents emerging for Richter’s transformation

Novel treatment strategies for Richter’s transformationПодробнее

Promising therapies for Richter's transformation: ven-R-CHOP, epcoritamab, pirtobrutinib & CAR-TПодробнее

Investigating the biology of Richter’s transformationПодробнее

Treating Richter’s transformation with venetoclax, obinutuzumab and atezolizumabПодробнее

Efficacy and safety of glofitamab for patients with Richter’s transformationПодробнее

Risk factors for Richter’s transformation in CLLПодробнее

Var-cel shows promise for the treatment of CLL and Richter's transformationПодробнее

Richter’s transformation: the need for more therapeutic agents in this spaceПодробнее

The use of NGS in the diagnosis and treatment of Richter’s transformationПодробнее

Treatment of Richter’s transformation: recent insightsПодробнее

How to treat Richter’s transformationПодробнее

How Can I Ensure My CLL Doesn’t Progress to Richter’s Transformation?Подробнее

The genomics of Richter's transformation and evolutionary history of RT from CLLПодробнее

Richter’s syndrome: What are the options?Подробнее

Latest advances in the management of Richter’s transformation and future outlooksПодробнее

The evolution of alloSCT in Richter's transformation and its combination with biological agentsПодробнее

Nivolumab + ibrutinib for patients with Richter’s transformationПодробнее

Improving upon the standard of care for patients with Richter’s transformationПодробнее

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformationПодробнее